Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Share-based Compensation (2016 - 2025)

Karyopharm Therapeutics' Share-based Compensation history spans 14 years, with the latest figure at $3.9 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 1.01% year-over-year to $3.9 million; the TTM value through Dec 2025 reached $14.0 million, down 25.53%, while the annual FY2025 figure was $14.0 million, 23.75% down from the prior year.
  • Share-based Compensation reached $3.9 million in Q4 2025 per KPTI's latest filing, up from $2.8 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $15.1 million in Q2 2022 to a low of $2.8 million in Q3 2025.
  • Average Share-based Compensation over 5 years is $6.0 million, with a median of $5.4 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: soared 85.53% in 2022, then crashed 59.85% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $6.9 million in 2021, then decreased by 10.13% to $6.2 million in 2022, then decreased by 16.05% to $5.2 million in 2023, then fell by 25.43% to $3.9 million in 2024, then grew by 1.01% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Share-based Compensation are $3.9 million (Q4 2025), $2.8 million (Q3 2025), and $3.6 million (Q2 2025).